PHASE-I TRIAL OF PENTAMETHYLMELAMINE

  • 1 January 1982
    • journal article
    • research article
    • Vol. 66  (5) , 1227-1228
Abstract
Pentamethylmelamine, an analog of hexamethylmelamine developed for i.v. use, was administered to 42 patients in a phase I clinical trial. The dose ranged from 0.080 to 2.50 g/m2 per day .times. 5 and was repeated approximately every 3 wk. The dose-limiting toxic effects included moderate to severe nausea, vomiting and CNS toxicity. Myelosuppression was mild and was not dose-limiting. Antineoplastic activity was observed in 4 patients. Due to unacceptable gastrointestinal and CNS toxic effects from pentamethylmelamine at the active dose levels, disease-specific phase II trials are not recommended.

This publication has 0 references indexed in Scilit: